tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC) and IMARA (IMRA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Blueprint Medicines (BPMCResearch Report) and IMARA (IMRAResearch Report).

Blueprint Medicines (BPMC)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Blueprint Medicines today and set a price target of $100.00. The company’s shares closed last Thursday at $58.77, close to its 52-week low of $50.96.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -20.0% and a 28.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $89.00, representing a 41.0% upside. In a report issued on June 1, Jefferies also upgraded the stock to Buy with a $78.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

IMARA (IMRA)

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Hold rating on IMARA. The company’s shares closed last Thursday at $1.22, close to its 52-week low of $0.97.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.9% and a 23.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

IMARA has an analyst consensus of Hold, with a price target consensus of $1.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed